| Literature DB >> 30979199 |
João Augusto Oshiro Junior1, Marina Paiva Abuçafy2, Eloísa Berbel Manaia3, Bruna Lallo da Silva4, Bruna Galdorfini Chiari-Andréo5,6, Leila Aparecida Chiavacci7.
Abstract
This is a review of hybrid materials based on silica as an inorganic phase used as drug delivery systems (DDS). Silica based DDS have shown effectivity when compared with traditional delivery systems. They present advantages such as: (a) ability to maintain the therapeutic range with minor variations; (b) prevention of local and systemic toxic effects; (c) plasma concentrations increase of substances with a short half-life; and (d) reduction of the number of daily doses, which may increase patient adherence to the treatment. These advantages occur due to the physical, chemical and optical properties of these materials. Therefore, we discuss the properties and characteristics of them and we present some applications, using different approaches of DDS to ensure therapeutic effectiveness and side effects reduction such as implantable biomaterial, film-forming materials, stimuli-responsive systems and others.Entities:
Keywords: drug delivery systems; organic-inorganic materials; sol-gel process
Year: 2016 PMID: 30979199 PMCID: PMC6432574 DOI: 10.3390/polym8040091
Source DB: PubMed Journal: Polymers (Basel) ISSN: 2073-4360 Impact factor: 4.329
Figure 1Representation of (A) Class I; (B) Class II; and (C) Class III of organic-inorganic hybrid materials. The white symbols represent the inorganic phase and the black ones represent the organic phase (adapted from the study by Benvenutti et al., 2009 [33]).
Figure 2Number of publications which contains the terms “organic-inorganic” and “drug delivery” (ISI: Web of Science, accessed on 28 August 2015 [50]).
Figure 3Schema of stimuli-responsive organic-inorganic materials for drug delivery systems (adapted from the study by Santilli et al., 2009 [60]).
Figure 4Bone defect repair using biomaterials: (a) the biomaterial releases bioactive molecules that interact with the bone cells; (b) it increases the quantity of bone tissue and occurs the degradation of the biomaterial, and finally; (c) occurs the regeneration of the tissue without presence of biomaterial.
Figure 5Molecules and biological interactions of ureasil-PEO and ureasil-PPO hybrid materials. Possible sites of bonding with the biological substrate and drugs are highlighted in the blue circles [64].
Figure 6Possible links between sites of hybrid material and molecules (I, II and III) [60].
Composition and time of release of drug to selected organic-inorganic systems.
| Organic-Inorganic System Composition | Drug | Time of Released of Drug | Comments | Reference |
|---|---|---|---|---|
| PVA/PNIPAAm | Rhodamine B | 16 h = ± 95% at 38 °C | Temperature influences in the release behavior | [ |
| BTEPAA | Doxorubicin | 48 h = ± 10% in pH ≤ 9 and | pH responsive systems | [ |
| Cs/MSM | Ibuprofen | 4 h = ± 20% in pH 7.4 and | pH responsive systems | [ |
| NAS/NAphMA/OEGMA/MSM | Rhodamine B | 4 h = ± 95% with 20 mM DDT | Fluorescence properties | [ |
| PEO/3-(isocyanatopropyl)-triethoxysilane/Magnetite | Sodium diclofenac | 4 h = ± 95% with the application magnetic and 80% without magnetic field (0.250 T, 220 kHz) | Stimulis with Magnetic field | [ |
| Pluronic/Tetraethyl orthosilicate/P2O5/H3PO4 | Alendronate | 4 h = 25 µg·m−2 to material without P2O5 and 87 µg·m−2 to material with P2O5 | Implantable systems | [ |
| PLGA/PS | Gentamicin | 24 h = 77% PLGA pure and 41% PLGA/PS. | Implantable Systems | [ |
| PEO/3-(isocyanatopropyl)-triethoxysilane/Chitosan | Pramoxine | 3 h = ± 100% without chitosan and 30% with 3% of chitosan | Film-forming systems | [ |
| Pluronic(127)/CPPs/Tetraethyl orthosilicateas | FITC/octaarginine | 5 days = 85% | New devices of DDS | [ |